Constipation Treatment Market

Constipation Treatment Market (Therapeutic Option - Laxatives (Bulk Forming Agents, Osmotic Laxatives, and Stimulant Laxatives), Chloride Channel Activators, Peripherally Acting Mu Opioid Receptor Antagonists, GC-C Agonists, and 5-HT4 Receptor Agonists; Disease Type - Chronic Idiopathic Constipation, Irritable Bowel Syndrome with Constipation, and Opioid Induced Constipation; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Global Constipation Treatment Market: Snapshot

The demand in the global market for constipation treatment is projected to increment at a healthy CAGR of 7.1% during the forecast period of 2017 to 2025. This prosperity of the constipation treatment market is primarily a reflection of escalating geriatric population across the globe, as people aged over 50 years are highly prone to irregular bowel movement. Consistent research and development to develop novel drugs that are more efficient, improving healthcare infrastructure in various emerging economies, and growing awareness among the end-users are some of the other factors favoring the global constipation treatment market. On the other hand, continued reliance of the patients on over-the-counter drugs and vast unmet demands in rural areas of developing countries is hindering the proper prosperity of the global constipation treatment market. Evaluated to have a worth of US$12.58 bn in 2016, the global constipation treatment market is estimated to reach a valuation of US$22.93 bn by the end of the forecast period, which is 2025.

 

constipation treatment market

 

Laxatives Remain Highly Profitable Therapeutic Segment

On the basis of therapeutic option, the global market for constipation treatment is segmented into laxatives, peripherally acting mu opioid receptor antagonists, chloride channel activators, GC-C agonists, and 5-HT4 receptor agonists. In 2016, the laxatives segment, which is further categorized into bulk forming agents, stimulant laxatives, and osmotic laxatives, accounted for the maximum demand-share. Over the course of the forecast period, the laxatives segment is anticipated to be most promising and dominate the market share. Affordability for the masses owing to low cost and wide availability are two key factors leading to the prosperity of this laxatives segment. That being said, GC-C agonists segment is projected for the best CAGR of 8.7% from 2017 to 2025.

Based on the type of disease, the global constipation treatment market is bifurcated into irritable bowel syndrome with constipation, chronic idiopathic constipation, and opioid induced constipation. The opioid induced constipation segment is projected to expand at CAGR of 7.5% during the forecast period from 2017 to 2025. Based on distribution channel, global market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies segment is projected to hold major share of global constipation treatment market in the near future.

Asia Pacific Projected for Most Impressive Growth Rate

Geographically, the global constipation treatment market has been classified into six major regions, viz. North America, Asia Pacific, Europe, Latin America, The Middle East & Africa, and Commonwealth of Independent States. In 2017, North America served the maximum demand in the constipation treatment market, owing to high prevalence of chronic constipation, high per capita healthcare expenditure, and availability of specialty constipation medicines. The North America constipation market is estimated to be worth US$9.98 bn by the end of 2025. Europe currently is second most lucrative region for the vendors operating in this market, however, Asia Pacific is anticipated to turn into a region-of-focus, with its considerably established market in emerging economies. Japan, India, and China are identified as three emerging country-wide markets for constipation treatment.

Some of the key players currently holding a position of strength in the global constipation market are: Bayer AG, Ironwood Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Limited, Sanofi, AstraZeneca, Abbott Laboratories, Sucampo Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, Inc., Janssen Pharmaceutical Company, Daewoong Pharmaceuticals Co. Ltd., Prestige Brands Holdings, Inc., Shionogi & Co., Ltd., Renexxion, LLC., Albireo Pharma, Inc., and Cosmo Pharmaceuticals NV.

New Medical Management Approaches Enrich Constipation Treatment Market

Constipation has been associated with high prevalence among worldwide populations, with chronic constipation usually leading to a dramatic fall in the quality of life in affected individuals. The high costs of OTC laxatives, due to prolonged reliance, and frequent doctor visits are factors that add to the psychological distress. Thus, there is a massive unmet need for proper medical management of chronic, propelling lifestyle modifications and medications. A severe case of distress comes from constipation-predominant irritable bowel syndrome (IBS). Aside from the common recommendations for lifestyle modifications, pharmacologic management has gained widespread traction in adolescents and young adults. Growing research in medical management of constipation is a key trend bolstering the growth potential of the constipation treatment market. Advances in diagnostic technologies and the chronic nature of the conditions force individuals to undergo extensive diagnostic evaluation. The growing number of patients diagnosed with rectal sensorimotor dysfunction has spurred R&D in the constipation treatment market. Some of the common diagnostic evaluations propelling the demand for medical management of constipation are endoscopy, anorectal manometry, and colonic transit study. Equipment used in these procedures have notably undergone marked technological advancements, aiding in the prognosis of chronic constipation. A number of dietary and drug approaches have emerged for managing chronic constipation, thereby boosting the prospects of the constipation market.

The COVID-19 pandemic and the still emerging outbreaks in new waves have been cause for governments and industry stakeholders. On one hand, policy makers are burdened with responsibility to upgrade the medical infrastructure to meet the drastically changing needs of the pandemic. On the other hand, maintaining a healthy flow of finances and money seems to be an unsurmountable challenge. The work-at-home has become a norm rather than exception and has remained so for the past several months in 2020 and in 2021 also. This has changed the whole dynamics of health and wellness. These disruptions are also likely to play a crucial role redefining the contours of the constipation treatment market in the near future.

The global constipation treatment market has been segmented as below:

by Therapeutic Option

  • Laxatives
    • Bulk forming agents
    • Osmotic laxatives
    • Stimulant laxatives
    • Others
  • Chloride channel activators
  • Peripherally Acting Mu-Opioid Receptor Antagonists
  • GC-C Agonists
  • 5-HT4 Receptor Agonists

by Disease Type

  • Chronic idiopathic constipation (CIC)
  • Irritable bowel syndrome with constipation (IBS-C)
  • Opioid-induced constipation (OIC)

by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

by Switches and Multiplexer Type

  • Analog
  • Buffered
  • Protocol Specific

by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Philippines
    • Thailand
    • Indonesia
    • Malaysia
    • Singapore
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Ecuador
    • Peru
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa
  • Commonwealth of Independent States
    • Russian Federation
    • Ukraine
    • Kazakhstan

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Constipation Treatment Market 

    4. Market Overview
         4.1. Introduction
                4.1.1. Product Definition
                4.1.2. Industry Evolution / Developments
         4.2. Market Overview
         4.3. Key Market Indicators
         4.4. Market Dynamics
                4.4.1. Drivers
                4.4.2. Restraints
                4.4.3. Opportunities
         4.5. Constipation Treatment Market Analysis and Forecast, 2017 – 2025
                4.5.1. Market Revenue Projections (US$ Mn)
         4.6. Porter’s five forces analysis
         4.7. Global Prevalence of Chronic Constipation
         4.8. Global Prevalence if Irritable Bowel Syndrome
         4.9. Pipeline Analysis
         4.10. Value Chain Analysis
         4.11. Market Outlook

    5. Global Constipation Treatment Market Analysis and Forecasts, By Therapeutic Option
         5.1. Introduction & Definition
         5.2. Key Findings
         5.3. Key Trends
         5.4. Market Size (US$ Mn) Forecast, By Therapeutic Option
                5.4.1. Laxatives
                           5.4.1.1. Bulk forming agents
                           5.4.1.2. Osmotic laxatives
                           5.4.1.3. Stimulant laxatives
                           5.4.1.4. Others
                5.4.2. Chloride channel activators
                5.4.3. Peripherally Acting Mu-Opioid Receptor Antagonists
                5.4.4. GC-C Agonists
                5.4.5. 5-HT4 Receptor Agonists
         5.5. New Chronic Constipation Therapies Market Revenue (US$) Forecast, 2017-2025
         5.6. Market Attractiveness, By Therapeutic Option

    6. Global Constipation Treatment Market Analysis and Forecasts, By Disease Type
         6.1. Introduction & Definition
         6.2. Key Findings 
         6.3. Key Trends
         6.4. Market Size (US$ Mn) Forecast, By Disease Type
                6.4.1. Chronic idiopathic constipation (CIC)
                6.4.2. Irritable bowel syndrome with constipation (IBS-C)
                6.4.3. Opioid-induced constipation (OIC)
         6.5. Market Attractiveness, By Disease Type

    7. Global Constipation Treatment Market Analysis and Forecasts, By Distribution Channel
         7.1. Introduction & Definition
         7.2. Key Findings 
         7.3. Key Trends
         7.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
                7.4.1. Hospital Pharmacies
                7.4.2. Retail Pharmacies
                7.4.3. Online Pharmacies
         7.5. Market Attractiveness, By Distribution Channel

    8. Global Constipation Treatment Market Analysis and Forecasts, By Region
         8.1. Introduction & Definition
         8.2. Key Findings 
         8.3. Key Trends
         8.4. Market Size (US$ Mn) Forecast, By Region
                8.4.1. North America
                8.4.2. Europe
                8.4.3. Asia Pacific
                8.4.4. Latin America
                8.4.5. Middle East and Africa
                8.4.6. Commonwealth of Independent States
         8.5. Market Attractiveness, By Region

    9. North America Constipation Treatment Market Analysis and Forecast
         9.1. Introduction
         9.2. Key Findings 
         9.3. Key Trends
         9.4. Market Size (US$ Mn) Forecast, By Therapeutic Option
                9.4.1. Laxatives
                           9.4.1.1. Bulk forming agents
                           9.4.1.2. Osmotic laxatives
                           9.4.1.3. Stimulant laxatives
                           9.4.1.4. Others
                9.4.2. Chloride channel activators
                9.4.3. Peripherally Acting Mu-Opioid Receptor Antagonists
                9.4.4. GC-C Agonists
         9.5. Market Size (US$ Mn) Forecast, By Disease Type
                9.5.1. Chronic idiopathic constipation (CIC)
                9.5.2. Irritable bowel syndrome with constipation (IBS-C)
                9.5.3. Opioid-induced constipation (OIC)
         9.6. Market Size (US$ Mn) Forecast, By Distribution Chanel
                9.6.1. Hospital Pharmacies
                9.6.2. Retail Pharmacies
                9.6.3. Online Pharmacies
         9.7. Market Size by Value (US$ Mn) Forecast, By Country
                9.7.1. The U.S.
                9.7.2. Canada
         9.8. Market Attractiveness Analysis 
                9.8.1. By Therapeutic Option
                9.8.2. By Disease Type
                9.8.3. By Distribution Channel
                9.8.4. By Country

    10.  Europe Constipation Treatment Market Analysis and Forecast
         10.1. Introduction
         10.2. Key Findings 
         10.3. Key Trends
         10.4. Market Size (US$ Mn) Forecast, By Therapeutic Option
                10.4.1. Laxatives
                           10.4.1.1. Bulk forming agents
                           10.4.1.2. Osmotic laxatives
                           10.4.1.3. Stimulant laxatives
                           10.4.1.4. Others
                10.4.2. Chloride channel activators
                10.4.3. Peripherally Acting Mu-Opioid Receptor Antagonists
                10.4.4. GC-C Agonists
                10.4.5. 5-HT4 Receptor Agonists
         10.5. Market Size (US$ Mn) Forecast, By Disease Type
                10.5.1. Chronic idiopathic constipation (CIC)
                10.5.2. Irritable bowel syndrome with constipation (IBS-C)
                10.5.3. Opioid-induced constipation (OIC)
         10.6. Market Size (US$ Mn) Forecast, By Distribution Chanel
                10.6.1. Hospital Pharmacies
                10.6.2. Retail Pharmacies
                10.6.3. Online Pharmacies
         10.7. Market Size by Value (US$ Mn) Forecast, By Country
                10.7.1. Germany
                10.7.2. France
                10.7.3. U.K.
                10.7.4. Spain
                10.7.5. Italy
                10.7.6. Rest of Europe
         10.8. Market Attractiveness Analysis 
                10.8.1. By Therapeutic Option
                10.8.2. By Disease Type
                10.8.3. By Distribution Channel
                10.8.4. By Country

    11.  Asia Pacific Constipation Treatment Market Analysis and Forecast
         11.1. Introduction
         11.2. Key Findings 
         11.3. Regulatory Scenario 
         11.4. Key Trends
         11.5. Market Size (US$ Mn) Forecast, By Therapeutic Option
                11.5.1. Laxatives
                           11.5.1.1. Bulk forming agents
                           11.5.1.2. Osmotic laxatives
                           11.5.1.3. Stimulant laxatives
                           11.5.1.4. Others
                11.5.2. Chloride channel activators
                11.5.3. Peripherally Acting Mu-Opioid Receptor Antagonists
                11.5.4. GC-C Agonists
                11.5.5. 5-HT4 Receptor Agonists
         11.6. Market Size (US$ Mn) Forecast, By Disease Type
                11.6.1. Chronic idiopathic constipation (CIC)
                11.6.2. Irritable bowel syndrome with constipation (IBS-C)
                11.6.3. Opioid-induced constipation (OIC)
         11.7. Market Size (US$ Mn) Forecast, By Distribution Chanel
                11.7.1. Hospital Pharmacies
                11.7.2. Retail Pharmacies
                11.7.3. Online Pharmacies
         11.8. Market Size by Value (US$ Mn) Forecast, By Country
                11.8.1. Philippines
                11.8.2. Thailand
                11.8.3. Indonesia
                11.8.4. South Korea
                11.8.5. Singapore
                11.8.6. Malaysia
                11.8.7. Rest of Asia Pacific
         11.9. Market Attractiveness Analysis 
                11.9.1. By Therapeutic Option
                11.9.2. By Disease Type
                11.9.3. By Distribution Channel
                11.9.4. By Country

    12.  Latin America Constipation Treatment Market Analysis and Forecast
         12.1. Introduction
         12.2. Key Findings 
         12.3. Regulatory Scenario 
         12.4. Key Trends
         12.5. Market Size (US$ Mn) Forecast, By Therapeutic Option
                12.5.1. Laxatives
                           12.5.1.1. Bulk forming agents
                           12.5.1.2. Osmotic laxatives
                           12.5.1.3. Stimulant laxatives
                           12.5.1.4. Others
                12.5.2. Chloride channel activators
                12.5.3. Peripherally Acting Mu-Opioid Receptor Antagonists
                12.5.4. GC-C Agonists
                12.5.5. 5-HT4 Receptor Agonists
         12.6. Market Size (US$ Mn) Forecast, By Disease Type
                12.6.1. Chronic idiopathic constipation (CIC)
                12.6.2. Irritable bowel syndrome with constipation (IBS-C)
                12.6.3. Opioid-induced constipation (OIC)
         12.7. Market Size (US$ Mn) Forecast, By Distribution Chanel
                12.7.1. Hospital Pharmacies
                12.7.2. Retail Pharmacies
                12.7.3. Online Pharmacies
         12.8. Market Size by Value (US$ Mn) Forecast, By Country
                12.8.1. Brazil
                12.8.2. Mexico
                12.8.3. Argentina
                12.8.4. Ecuador
                12.8.5. Peru
                12.8.6. Rest of Latin America
         12.9. Market Attractiveness Analysis 
                12.9.1. By Therapeutic Option
                12.9.2. By Disease Type
                12.9.3. By Distribution Channel
                12.9.4. By Country

    13.  Middle East and Africa Constipation Treatment Market Analysis and Forecast
         13.1. Introduction
         13.2. Key Findings 
         13.3. Regulatory Scenario      
         13.4. Key Trends
         13.5. Market Size (US$ Mn) Forecast, By Therapeutic Option
                13.5.1. Laxatives
                           13.5.1.1. Bulk forming agents
                           13.5.1.2. Osmotic laxatives
                           13.5.1.3. Stimulant laxatives
                           13.5.1.4. Others
                13.5.2. Chloride channel activators
                13.5.3. Peripherally Acting Mu-Opioid Receptor Antagonists
                13.5.4. GC-C Agonists
                13.5.5. 5-HT4 Receptor Agonists
         13.6. Market Size (US$ Mn) Forecast, By Disease Type
                13.6.1. Chronic idiopathic constipation (CIC)
                13.6.2. Irritable bowel syndrome with constipation (IBS-C)
                13.6.3. Opioid-induced constipation (OIC)
         13.7. Market Size (US$ Mn) Forecast, By Distribution Chanel
                13.7.1. Hospital Pharmacies
                13.7.2. Retail Pharmacies
                13.7.3. Online Pharmacies
         13.8. Market Size by Value (US$ Mn) Forecast, By Country
                13.8.1. Saudi Arabia
                13.8.2. South Africa
                13.8.3. Rest of Middle East and Africa
         13.9. Market Attractiveness Analysis 
                13.9.1. By Therapeutic Option
                13.9.2. By Disease Type
                13.9.3. By Distribution Channel
                13.9.4. By Country

    14.  Commonwealth of Independent States Constipation Treatment Market Analysis and Forecast
         14.1. Introduction
         14.2. Key Findings 
         14.3. Market Size (US$ Mn) Forecast, By Therapeutic Option
                14.3.1. Laxatives
                           14.3.1.1. Bulk forming agents
                           14.3.1.2. Osmotic laxatives
                           14.3.1.3. Stimulant laxatives
                           14.3.1.4. Others
                14.3.2. Chloride channel activators
                14.3.3. Peripherally Acting Mu-Opioid Receptor Antagonists
                14.3.4. GC-C Agonists
                14.3.5. 5-HT4 Receptor Agonists
         14.4. Market Size (US$ Mn) Forecast, By Disease Type
                14.4.1. Chronic idiopathic constipation (CIC)
                14.4.2. Irritable bowel syndrome with constipation (IBS-C)
                14.4.3. Opioid-induced constipation (OIC)
         14.5. Market Size (US$ Mn) Forecast, By Distribution Chanel
                14.5.1. Hospital Pharmacies
                14.5.2. Retail Pharmacies
                14.5.3. Online Pharmacies
         14.6. Market Size by Value (US$ Mn) Forecast, By Country
                14.6.1. Russian Federation
                14.6.2. Ukraine
                14.6.3. Kazakhstan
         14.7. Market Attractiveness Analysis 
                14.7.1. By Therapeutic Option
                14.7.2. By Disease Type
                14.7.3. By Distribution Channel
                14.7.4. By Country

    15.  Competition Landscape
         15.1. Market Player – Competition Matrix (By Tier and Size of companies)
         15.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
                15.2.1. Takeda Pharmaceutical Company Ltd
                           15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.1.2. Product Portfolio
                           15.2.1.3. SWOT Analysis
                           15.2.1.4. Financial Overview
                           15.2.1.5. Strategic Overview
                15.2.2. Synergy Pharmaceuticals, Inc.
                           15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.2.2. Product Portfolio
                           15.2.2.3. SWOT Analysis
                           15.2.2.4. Financial Overview
                           15.2.2.5. Strategic Overview
                15.2.3. Sucampo Pharmaceuticals, Inc.
                           15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.3.2. Product Portfolio
                           15.2.3.3. SWOT Analysis
                           15.2.3.4. Financial Overview
                           15.2.3.5. Strategic Overview
                15.2.4. Ironwood Pharmaceuticals, Inc.
                           15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.4.2. Product Portfolio
                           15.2.4.3. SWOT Analysis
                           15.2.4.4. Financial Overview
                           15.2.4.5. Strategic Overview
                15.2.5. Valeant Pharmaceuticals International, Inc.
                           15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.5.2. Product Portfolio
                           15.2.5.3. SWOT Analysis
                           15.2.5.4. Financial Overview
                           15.2.5.5. Strategic Overview
                15.2.6. Abbott Laboratories
                           15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.6.2. Product Portfolio
                           15.2.6.3. SWOT Analysis
                           15.2.6.4. Financial Overview
                           15.2.6.5. Strategic Overview
                15.2.7. AstraZeneca
                           15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.7.2. Product Portfolio
                           15.2.7.3. SWOT Analysis
                           15.2.7.4. Financial Overview
                           15.2.7.5. Strategic Overview
                15.2.8. Cosmo Pharmaceuticals NV
                           15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.8.2. Product Portfolio
                           15.2.8.3. SWOT Analysis
                           15.2.8.4. Financial Overview
                           15.2.8.5. Strategic Overview
                15.2.9. Sanofi
                           15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.9.2. Product Portfolio
                           15.2.9.3. SWOT Analysis
                           15.2.9.4. Financial Overview
                           15.2.9.5. Strategic Overview
                15.2.10. Daewoong Pharmaceuticals Co. Ltd.
                           15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.10.2. Product Portfolio
                           15.2.10.3. SWOT Analysis
                           15.2.10.4. Financial Overview
                           15.2.10.5. Strategic Overview
                15.2.11. Bayer AG
                           15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.11.2. Product Portfolio
                           15.2.11.3. SWOT Analysis
                           15.2.11.4. Financial Overview
                           15.2.11.5. Strategic Overview
                15.2.12. Prestige Brands Holdings, Inc.
                           15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.12.2. Product Portfolio
                           15.2.12.3. SWOT Analysis
                           15.2.12.4. Financial Overview
                           15.2.12.5. Strategic Overview
                15.2.13. Janssen Pharmaceutical Company
                           15.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.13.2. Product Portfolio
                           15.2.13.3. SWOT Analysis
                           15.2.13.4. Financial Overview
                           15.2.13.5. Strategic Overview
                15.2.14. Shionogi & Co., Ltd.
                           15.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.14.2. Product Portfolio
                           15.2.14.3. SWOT Analysis
                           15.2.14.4. Financial Overview
                           15.2.14.5. Strategic Overview
                15.2.15. Albireo Pharma, Inc.
                           15.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.15.2. Product Portfolio
                           15.2.15.3. SWOT Analysis
                           15.2.15.4. Financial Overview
                           15.2.15.5. Strategic Overview
                15.2.16. Renexxion, LLC
                           15.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)
                           15.2.16.2. Product Portfolio
                           15.2.16.3. SWOT Analysis
                           15.2.16.4. Strategic Overview

    16. Key Takeaways

    List of Tables

    Table 01: Pipeline Analysis, By Phase 3 Drugs
    Table 02 : Pipeline Analysis, By Phase 2 (1/2)
    Table 03: Pipeline Analysis, By phase 2 (2/2)
    Table 04: Global Constipation Treatment Market Size (US$ Mn) Forecast, by Therapeutic Option, 2015–2025
    Table 05: Global Constipation Treatment Market Size (US$ Mn) Forecast, by Laxatives, 2015–2025
    Table 06: Global Constipation Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 07: Global Constipation Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 08: Global Constipation Treatment Market Size (US$ Mn) Forecast, by Region, 2015–2025
    Table 09: North America Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option,2015–2025
    Table 10: North America Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
    Table 11: North America Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 12: North America Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel,2015–2025
    Table 13: North America Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region,2015–2025
    Table 14: Europe Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option, 2015–2025
    Table 15: Europe Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
    Table 16: Europe Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 17: Europe Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 18: Europe Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 19: Asia Pacific Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option, 2015–2025
    Table 20: Asia Pacific Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
    Table 21: Asia Pacific Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 22: Asia Pacific Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 23: Asia Pacific Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 24: Latin America Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option,2015–2025
    Table 25: Latin America Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
    Table 26: Latin America Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 27: Latin America Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel,2015–2025
    Table 28: Latin America Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 29: Middle East & Africa Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option, 2015–2025
    Table 30: Middle East & Africa Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
    Table 31: Middle East & Africa Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 32: Middle East & Africa Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 33: Middle East & Africa Constipation Treatment Market Value (US$ Mn) Forecast, by Country, 2015–2025
    Table 34: CIS Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option, 2015–2025
    Table 35: CIS Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
    Table 36: CIS Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 37: CIS Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 38: CIS Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025

    List of Figures

    Figure 01: Global Constipation Treatment Market, by Therapeutic Option, Market Size (US$ Mn), 2016 (A)
    Figure 02: Global Constipation Treatment Market Revenue (%), by Disease Type, 2016 (A)
    Figure 03: Global Constipation Treatment Market Size (US$ Mn) Forecast, 2015–2025
    Figure 04: Global Prevalence of Constipation
    Figure 05: Global Prevalence of Irritable Bowel Syndrome
    Figure 06: Market Value Share, by Therapeutic Option (2016)
    Figure 07: Market Value Share, by Disease Type (2016)
    Figure 08: Market Value Share, by Distribution Channel (2016)
    Figure 09: Global Constipation Treatment Market Value Share, by Therapeutic Option, 2016 and 2025
    Figure 10: Global Constipation Treatment Market Attractiveness, by Therapeutic Option, 2017–2025
    Figure 11: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Laxatives, 2015–2025
    Figure 12: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chloride Channel Activator, 2015–2025
    Figure 13: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by PAMORA 2015–2025
    Figure 14: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by GC-C Agonists, 2015–2025
    Figure 15: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by 5-HT4 Receptor Agonists 2015–2025
    Figure 16: Global Constipation Treatment Market Value Share, by Disease Type, 2016 and 2025
    Figure 17: Global Constipation Treatment Market Attractiveness, by Disease Type, 2017–2025
    Figure 18: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CIC, 2015–2025
    Figure 19: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by IBS-C, 2015–2025
    Figure 20: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by OIC, 2015–2025
    Figure 21: Global Constipation Treatment Market Value Share, by Distribution Channel, 2016 and 2025
    Figure 22: Global Constipation Treatment Market Attractiveness, by Distribution Channel, 2017–2025
    Figure 23: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
    Figure 24: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015–2025
    Figure 25: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015–2025
    Figure 26: Global Constipation Treatment Market Value Share, by Region, 2017 and 2025 
    Figure 27: Global Constipation Treatment Market Attractiveness, by Region, 2017–2025
    Figure 28: North America Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 29: North America Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
    Figure 30: North America Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 31: North America Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 32: North America Constipation Treatment Market Value Share Analysis, by Country, 2016 and 2025
    Figure 33: North America Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
    Figure 34: North America Constipation Treatment Market Attractiveness Analysis, by Disease Type
    Figure 35: North America Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
    Figure 36: North America Constipation Treatment Market Attractiveness Analysis, by Country
    Figure 37: Europe Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 38: Europe Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
    Figure 39: Europe Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 40: Europe Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 41: Europe Constipation Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 42: Europe Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
    Figure 43: Europe Constipation Treatment Market Attractiveness Analysis, by Disease Type
    Figure 44: Europe Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
    Figure 45: Europe Constipation Treatment Market Attractiveness Analysis, by Country/Sub-region
    Figure 46: Asia Pacific Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 47: Asia Pacific Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
    Figure 48: Asia Pacific Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 49: Asia Pacific Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 50: Asia Pacific Constipation Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 51: Asia Pacific Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
    Figure 52: Asia Pacific Constipation Treatment Market Attractiveness Analysis, by Disease Type
    Figure 53: Asia Pacific Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
    Figure 54: Asia Pacific Constipation Treatment Market Attractiveness Analysis, by Country
    Figure 55: Latin America Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 56: Latin America Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
    Figure 57: Latin America Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 58: Latin America Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 59: Latin America Constipation Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 60: Latin America Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
    Figure 61: Latin America Constipation Treatment Market Attractiveness Analysis, by Disease Type
    Figure 62: Latin America Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
    Figure 63: Latin America Constipation Treatment Market Attractiveness Analysis, by Country/Sub-region
    Figure 64: Middle East & Africa Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 65: Middle East & Africa Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
    Figure 66: Middle East & Africa Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 67: Middle East & Africa Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 68: Middle East & Africa Constipation Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 69: Middle East & Africa Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
    Figure 70: Middle East & Africa Constipation Treatment Market Attractiveness Analysis, by Disease Type
    Figure 71: Middle East & Africa Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
    Figure 72: Middle East & Africa Constipation Treatment Market Attractiveness Analysis, by Country/Sub-region
    Figure 73: CIS Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 74: CIS Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
    Figure 75: CIS Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 76: CIS Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 77: CIS Constipation Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 78: CIS Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
    Figure 79: CIS Constipation Treatment Market Attractiveness Analysis, by Disease Type
    Figure 80: CIS Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
    Figure 81: CIC Constipation Treatment Market Attractiveness Analysis, by Country/Sub-region

Copyright © Transparency Market Research, Inc. All Rights reserved